Oral versus vaginal Lactobacillus supplementation for endometrial dysbiosis: A paired pre and post-endometrial microbiome study.
OA: gold
CC-BY-4.0
Abstract
Infertility is a global health challenge, and impaired endometrial receptivity remains an important contributor to treatment failure. Endometrial dysbiosis, characterized by a low proportion of Lactobacillus in the endometrial microbiota, has been proposed as a potentially modifiable factor that may affect endometrial receptivity and fertility, and treatment with Lactobacillus-containing probiotics is emerging as a promising therapeutic approach. However, the optimal route of Lactobacillus supplementation remains unclear. We compared oral versus vaginal supplementation using the same Lactobacillus-containing formulation as an adjunct to standardized doxycycline/metronidazole therapy and continued oral lactoferrin in patients with baseline endometrial Lactobacillus <10%, based on paired microbiome profiling of endometrial samples (aspirated intrauterine fluid and endometrial tissue). In this single-center retrospective cohort study, thirty-two patients underwent paired endometrial microbiome testing before and after 30 days of supplementation (oral, n = 18; vaginal, n = 14). In the vaginal group, the median endometrial Lactobacillus proportion increased from 0.05% [0.00-0.20] to 99.15% [70.45-100.00] (p = 0.001), whereas in the oral group it increased from 0.00% [0.00-0.18] to 0.30% [0.03-66.33] (p = 0.005). The median change was greater with vaginal versus oral supplementation (+98.90% [70.45-99.80] vs + 0.25% [0.03-66.33], p < 0.001). Post-treatment Lactobacillus ≥80%, used as an exploratory marker of marked microbiota improvement, was observed in 9/14 patients (64%) in the vaginal group and 3/18 (17%) in the oral group (p = 0.010). Exploratory reproductive outcomes were limited by the small sample size and did not define a reliable clinical threshold. These findings suggest that, within this combined treatment regimen, vaginal Lactobacillus supplementation may provide a greater route-associated additional improvement in endometrial microbiota profiles than oral administration.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2026) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.
SciLite annotations
organisms 69
paralactobacillus
paralactobacillus
microbiota
paralactobacillus
paralactobacillus
paralactobacillus
paralactobacillus
microbiota
paralactobacillus
microbiota
paralactobacillus
microbiota
paralactobacillus
microbiota
paralactobacillus
microbiota
paralactobacillus
paralactobacillus
microbiota
noordeloos 2009062
paralactobacillus
paralactobacillus
human
paralactobacillus
paralactobacillus
paralactobacillus
vkm:b:574
bacteria stick insect
paralactobacillus
paralactobacillus
paralactobacillus
microbiota
paralactobacillus
microbiota
microbiota
microbiota
paralactobacillus
paralactobacillus
microbiota
paralactobacillus
paralactobacillus
paralactobacillus
paralactobacillus
paralactobacillus
paralactobacillus
microbiota
paralactobacillus
paralactobacillus
microbiota
paralactobacillus
vkm b-1660
vkm:b:574
paralactobacillus
vpi 3199
lmg:18914
paralactobacillus
paralactobacillus
paralactobacillus
paralactobacillus
paralactobacillus
+9 more
chemicals 20
doxycycline
metronidazole
doxycycline
metronidazole
doxycycline
metronidazole
hydroxypropyl methylcellulose
carrageenan
potassium chloride
hexamethyldisiloxane
fatty acid ester
starch
calcium stearate
silicon dioxide
water
doxycycline
metronidazole
doxycycline
doxycycline
metronidazole
Source provenance
- europepmc
- last seen: 2026-11-01T09:25:17.647243+00:00
- scilite
- last seen: 2026-11-01T10:01:09.713090+00:00
License: CC-BY-4.0
· commercial use OK
· attribution required
Per Europe PMC
Per Europe PMC